. .

 
Zuruecksetzen

Suchergebnis - IDORSIA N

Zeit Titel
03.06 07:05GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024
31.05 07:05GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
23.05 07:05GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
21.05 07:05GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21.05 06:55GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor
21.05 06:45GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value
14.05 17:50GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
06.05 18:40GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds
01.05 18:05GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
26.04 07:05GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
23.04 07:05GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting
17.04 07:05GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting
11.04 07:05GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs
22.03 07:05GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires
20.03 07:05GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
18.03 07:05GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration
28.02 07:05GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration
10.01 07:05GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation
03.11 22:35GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
24.10 07:05GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH